EPIX ESSA Pharma
- 6.050
- -0.010-0.17%
- 6.050
- 0.0000.00%
ESSA Pharma News
Oppenheimer Maintains ESSA Pharma(EPIX.US) With Buy Rating, Maintains Target Price $17
ESSA Pharma (EPIX) Gets a Buy From Piper Sandler
ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans
Express News | ESSA Pharma - Combination of Masofaniten Plus Enzalutamide Continues to Be Well Tolerated With Durable Reductions in Psa in Patients With Mcrpc
Express News | ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 Esmo Congress
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress
We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely
ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference
Buy Rating Affirmed on ESSA Pharma Amid Promising MCRPC Therapy Data and Upcoming ESMO Conference Insights
ESSA Pharma (EPIX) Receives a Buy From Oppenheimer
Piper Sandler Maintains ESSA Pharma(EPIX.US) With Buy Rating, Maintains Target Price $15
Piper Sandler Sticks to Its Buy Rating for ESSA Pharma (EPIX)
JonesTrading Maintains ESSA Pharma(EPIX.US) With Buy Rating, Maintains Target Price $18
ESSA Pharma Advances Prostate Cancer Clinical Trials
ESSA Pharma GAAP EPS of -$0.16 Beats by $0.09
ESSA Pharma | 10-Q: Q3 2024 Earnings Report
Express News | ESSA Pharma: On Track to Report Updated Phase 1 Masofaniten Plus Enzalutamide Dose Escalation Data in H2 2024
Express News | ESSA Pharma Inc: Cash Runway Sufficient to Fund Operations Well Beyond 2025
Express News | ESSA Pharma Q3 Pretax Profit USD -7.233 Million
Express News | ESSA Pharma Q3 Operating Expenses USD -8.638 Million
Analysis
Price Target
No Data
No Data